The U.S. Department of Commerce has launched a new application process that could allow pharmaceutical companies to significantly reduce looming Section 232 tariffs if they commit to moving drug manufacturing operations to the United States.
Under the newly announced framework, branded and patented pharmaceutical products imported into the U.S. could face tariffs as high as 100% beginning later this year. However, companies willing to establish or expand domestic manufacturing facilities may qualify for sharply reduced tariff rates through “onshoring agreements” with the federal government.
The policy stems from President Donald Trump’s April 2026 proclamation invoking Section 232 of the Trade Expansion Act, which allows tariffs to be imposed on imports considered a national security concern. The administration argues that America has become overly dependent on foreign pharmaceutical manufacturing and vulnerable global supply chains.
According to the Commerce Department notice, companies that secure approved onshoring plans may receive a reduced 20% tariff rate instead of the default 100% duty. Firms that also enter into “most-favored-nation” drug pricing agreements with the U.S. government could potentially qualify for temporary zero tariffs until 2029.
The application process requires drugmakers to provide detailed plans covering manufacturing investments, timelines, product details, sourcing information, and long-term domestic production commitments. Applications must reportedly be submitted by June 12, 2026.
The move is expected to place major pressure on global pharmaceutical manufacturers, especially companies heavily dependent on overseas production hubs in countries such as India, China, and parts of Europe. Industry experts believe the policy could trigger significant restructuring of pharmaceutical supply chains over the next few years.
While generic medicines are currently exempt from the tariffs, analysts warn that the administration may review those exclusions in the future. Several healthcare industry groups have already raised concerns that aggressive tariffs could increase medicine costs and disrupt patient access if companies fail to secure relief agreements in time.
